Sanofi (SNY) Reports Positive Results in Phase 3 trial for Toujeo in Children & Adolescents with Type 1 Diabetes; CHMP Adopts Positive Opinion for Expanded Indication

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Sanofi (SNY) Reports Positive Results in Phase 3 trial for Toujeo in Children & Adolescents with Type 1 Diabetes; CHMP Adopts Positive Opinion for Expanded Indication

Sanofi : Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes

November 4, 2019 1:00 AM EST

Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes

* CHMP adopts positive opinion for expanded indication for Toujeo in children and adolescents (aged 6 to 17 years) with diabetes

PARIS November 4, 2019 Children and adolescents (aged 6 to 17 years) living with type 1 diabetes achieved comparable reduction in average blood sugar (HbA1c) and similar risk of low blood sugar events with Toujeo® (insulin glargine 300 Units/mL) compared to insulin glargine 100 Units/mL (Gla-100), according to results presented at the International Society for Pediatric and Adolescent Diabetes 45th Annual Conference in Boston,... More